Qsymia Set for Fourth-Quarter Launch with Reasonable REMS
Vivus Inc. shared details of its launch plans and risk evaluation and management strategy (REMS) for newly approved weight loss drug Qsymia (phentermine/topiramate) on an investor call Wednesday morning. Vivus is aiming for a fourth-quarter launch with a REMS that includes a medication guide delivered with each prescription, a health provider training program and distribution of the drug through certified pharmacies only.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter